Rutgers Project ECHO
Pain Management

Provided by Rutgers Robert Wood Johnson Medical School

Target Audience

This activity is designed for New Jersey Medicaid primary care and mid-level providers as well as social workers, pharmacists, and nurses.

Learning Objectives

After participating in ECHO, participants should be better able to:

1. Describe the screening tools useful for management of chronic pain in primary care setting including those measuring pain intensity, function, and addiction risk;
2. Identify pharmacologic and non-pharmacologic treatment modalities available for patients;
3. Self-regulate attitudes and beliefs about patient presentations to provide safe and effective chronic pain management; and,
4. Demonstrate ways to manage requests for opioid therapy from patients for whom this type of therapy is appropriate, and those for whom it is not appropriate.

Rutgers RWJMS Project ECHO Planning Committee

Eric Jahn, MD	Brittany Sullivan, MSPH	Ashley Figueroa, MPA
Kathy Dodsworth-Rugani, PhD	Brian Reid, MHA	Ruben Nanez
Mary Bridgeman, PharmD	Michelle Rupe, MSW	Suzanne Spernal, DNP

Pain Management ECHO Session Leaders

Scott Mellender, MD, Anesthesiologist & Pain Management Specialist, Rutgers Robert Wood Johnson Medical School
Vamsee K Chaguturu, MD, Addiction Psychiatrist, Rutgers Robert Wood Johnson Medical School
Mary Bridgeman, PharmD, BCPS, BCGP, Pharmacist, Rutgers Ernest Mario School of Pharmacy
Jason Womack, MD, Sports Medicine, Rutgers Robert Wood Johnson Medical School
Joyce Schneiderman, MD, Internist, Rutgers Robert Wood Johnson Medical School
Kate Hottinger, PhD, Pain Psychologist, Children Specialized Hospital
Oleksiy Lelyanov, DO, Pain Interventionalist, Rutgers Robert Wood Johnson Medical School
Sue Paparella-Pitzel, PT, MS, DPT, Physical Therapist, Rutgers School of Health Professions
Ann Hirschman, FNP, Field Utility Nurse, Independent Consultant

Accreditation

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

CME

Rutgers Biomedical and Health Sciences designates this live activity a maximum of 12 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each session is designated for a maximum of one (1) *AMA PRA Category 1 Credit*™.

CNE

This activity is awarded 12 contact hours. (60 minute CH) Each session is awarded a maximum of one (1) contact hour.

Nurses should only claim those contact hours actually spent participating in the activity.

CPE

This application-based activity qualifies for 12 contact hours of continuing pharmacy education credit. Each session qualifies for a maximum of one (1) contact hour of continuing pharmacy education credit.

Pharmacists should claim only those contact hours actually spent participating in the activity.

Social Workers (The New Jersey Board of Social Work Examiners): This program is approved for social work continuing education hours by Rutgers University Behavioral Health Care in accordance with New Jersey administrative code 13:44G-6.4 and recognized by The New Jersey Board of Social Work Examiners. This program is approved for 12 continuing education hours.

Method of Participation

In order to receive CE credit, participants must register for the ECHO, and complete the evaluation and credit request at the conclusion of each session. Participants will receive one statement of credit from Rutgers Biomedical and Health Sciences at the conclusion of the series.

Pharmacists: Your official record of ACPE credit will be generated through the CPE Monitor System on a monthly basis. Your NABP e-Profile ID and date of birth will be collected through the evaluation and credit request. Please note that you must complete the evaluation and credit request for each session by the requested date. Under ACPE Policy, Rutgers Biomedical and Health Sciences (RBHS) will not able to report your activity completion to CPE monitor if your NABP e-Profile ID and date of birth are reported to and received by RBHS more than 60 days following the activity.

Peer Review Statement

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by the steering committee.

Disclosure Disclaimer

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Financial Disclosure Declarations

The following session leaders have no relevant financial relationships to disclose:

Scott Mellender, MD
Vamsee K Chaguturu, MD
Oleksiy Lelyanov, DO
Ann Hirschman, FNP
Sue Paparella-Pitzel, PT, MS, DPT
Jason Womack, MD
Kate Hottinger, PhD
Joyce Schneiderman, MD

The following session leader and planning committee member has relevant financial relationships to disclose:

Mary Bridgeman, PharmD, – Member, Speakers Bureau: AstraZeneca

The following planning committee members have relevant financial relationships to disclose:

Eric Jahn, MD – Stock shareholder (directly purchased): Proctor & Gamble, Johnson & Johnson

Kathy Dodsworth-Rugani, PhD – Stock shareholder (directly purchased): Johnson & Johnson, Pfizer

The following planning committee members have no relevant financial relationships to disclose:

Brittany Sullivan, MSPH
Ashley Figueroa, MPA
Michelle Rupe, MSW
Ruben Nanez
Suzanne Spernel, APN
Brian Reid, MHA

Off-label/Investigational Use Disclosure

Speakers are required to disclose discussion of off-label/investigational uses of commercial products. These disclosures will be made to the audience at the time of the activity.